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Abstract 
X-linked inhibitor of apoptosis (XIAP), also referred 
to as BIRC4 or IAP3, is one of the most studied 
members among the proteins known as Inhibitors of 
Apoptosis Proteins (IAPs). This protein family 
portrays its main role by preventing apoptotic cell 
death through direct or indirect inhibition of caspase 
activity. All members of the IAPs carry at least one 
BIR domain in their structure, which are generally 
responsible for caspase interaction. XIAP has three 
BIR domains, enabling interaction with both 
initiation and effector caspases. Moreover, it is also 
structured with a RING finger domain, which 
functions as a ubiquitin ligase (E3), and one UBA 
domain, for binding to ubiquitin, further rendering 
XIAP a central role in the ubiquitination process and, 
thus, implicating such IAP in multiple signaling 
pathways, including cell death, autophagy, 
immunity, inflammation, cell cycle, and cell 
migration. XIAP overexpression is found in a variety 
of cancer types and is frequently associated with 
chemoresistance and increased risk of relapse. 
Furthermore, there are many evidences that XIAP 
inhibition may sensitize tumor cells to chemotherapy 
agents, which make this protein a potential target in 
cancer. 
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The entire XIAP gene is approximately 54.2 Kb 
(start: 123859724 bp; end: 123913979 bp; 
orientation: plus strand).  
There are two transcript variants deposited in the 
NCBI database 
(https://www.ncbi.nlm.nih.gov/gene).  
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Figure 1. XIAP protein structure.  XIAP (also known as BIRC4 or IAP3) presents two transcripts variants deposited in NCBI 
database. The protein structure presents 497 amino acids (aa) and is composed of three BIR domain being one of them that 
responsible for its anti-apoptotic activity, one RING zinc finger domain and an UBA domain. The XIAP structure containing their 
domains and the specific interactions of each domain, signaling the importance of XIAP in apoptotic pathways through interaction 
with caspases. The aa positions are indicated. 
 
The transcript variant 1 is the longest transcript 
(cDNA: 8460 bp), while transcript variant 2 differs 
in the 5' UTR, compared to transcript variant 1 
(cDNA: 8427 bp); however, both transcripts encode 
the same protein (497 aa). There are nine additional 
transcript variants reported in Ensembl 
(http://www.ensembl.org/): a transcript variant 
containing 8415 bp, which generates a protein of 497 
aa; a transcript variant containing 528 bp, which 
generates a protein of 156 aa; a transcript variant 
containing 390 bp, which generates a protein of 16 
aa; and six long non-coding RNA-related transcripts 
that do not generate proteins (764, 628, 598, 533, 495 
and 157 bp). 
Protein 
Description 
X-linked inhibitor of apoptosis (XIAP), also referred 
to as BIRC4, belongs to a family of proteins known 
as Inhibitors of Apoptosis Proteins (IAPs). This 
protein family is recognized, mainly, for inhibiting 
caspase activity, either directly or indirectly, thus 
preventing apoptotic cell death. Such propriety is 
generally associated to their distinctive BIR 
(baculovirus IAP repeat) domain, a conserved 
sequence of nearly 80 amino acids with a centered 
Zn+2, which may occur in numbers of one or three 
among members of this family. In fact, eight human 
IAPs have been described so far: BIRC1 ( NAIP), 
BIRC2 (cIAP1), BIRC3 (cIAP2), BIRC4 (XIAP), 
BIRC5 (Survivin), BIRC6 (Bruce), BIRC7 (Livin) 
and BIRC8 (ILP-2) (Silke and Vucic, 2014).  
XIAP presents three BIR domains located at the N-
terminus region as demonstrated in Figure 1. Despite 
similarities shared among BIR domains, their 
functions may vary according to the IAP member. 
BIR1 interacts with proteins that modulate NFKB1 
(NFκB) signaling (Lu et al., 2007). BIR2 and the 
linker region between BIR1 and BIR2 domain are 
necessary for inhibition of effector CASP3 and 
CASP7 (caspases-3 and -7) (Suzuki et al., 2001). 
BIR3 domain is responsible for inhibiting CASP9 
(caspase-9), thus, preventing the intrinsic apoptosis 
pathway (Lukacs et al., 2013). By contrast, diablo 
IAP-binding mitochondrial protein binds to both 
BIR2 and BIR3 domains, thus inhibiting their 
function, increasing the activation of CASP3, 
CASP7 and CASP9 (caspases-3, -7 and -9), and 
promoting apoptosis (Suzuki et al., 2001, Obexer 
and Ausserlechner, 2014).  
At its C-terminus region, XIAP carries a RING zinc 
finger domain. Although a BIR domain occurs 
among all IAPs, the RING domain, in turn, is found 
only in XIAP, BIRC2 and BIRC3. For XIAP, the 
RING domain involves an E3 ligase effect, 
indicating an important activity on protein ubiquitin 
process (Nakatani et al., 2013). Additionally, the 
RING domain was shown to be involved in NFKB1 
signaling and MYC proto-oncogene stability, 
contributing to cancer progression (Jiang et al., 
2019), and also on the migratory and invasive 
potential of cancer cells (Liu et al., 2012).   
Expression 
Vischioni and colleagues (2006) assessed XIAP 
expression in a variety of normal adult human tissues 
in an extensive study using immunohistochemistry, 
where it displayed an heterogenous pattern. Higher 
intensity immunoreactivity was mainly observed in 
the small intestine (specifically in Paneth cells and 
absorptive epithelium) and in epidermal 
keratinocytes within all the layers of the skin (except 
in stratum corneum). XIAP also displayed 
considerable immunoreactivity in specific areas of 
the stomach, large intestine, thymus, testicles, ovary 
and mammary gland. It has been found in a gradient 
within tissues such as squamous epithelia and in 
more differentiated cells in other tissues like 
esophageal epithelium (Vischioni et al., 2006).  
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Indeed, the expression of XIAP is not limited to cell 
types that are constantly undergoing apoptosis or 
tissues with faster cell turnover.  
Given that the main function of XIAP is to impair 
both intrinsic and extrinsic apoptosis pathways, this 
finding is of particular interest in oncology research, 
as mechanisms to avoid cell death are one of the 
main factors that contribute to the formation of solid 
tumor masses. Not coincidentally, upregulating 
XIAP expression is one of the means by which tumor 
cells may accomplish such resistance. Therefore, 
XIAP expression levels may directly determine the 
sensitivity of tumor cells to apoptosis (Eckelman et 
al., 2006; Yang et al., 2018).  
XIAP was found to be overexpressed in a variety of 
cancer types and is frequently associated with 
chemoresistance and increased risk of recurrence, 
being, generally, a predictive marker of poor 
prognosis of the disease (Srinivasula & Ashwell., 
2008; Obexer Ausserlechner, 2014). In this matter, 
Gao and colleagues (2019) conducted a systematic 
review and metanalysis to determine the prognostic 
value of XIAP in patients with different tumor types. 
The analysis included 40 articles and more than 
6,500 patients and concluded that the majority of the 
studies correlated high XIAP expression levels to an 
unfavorable prognostic factor for clinical outcomes 
in cancer patients (Gao et al., 2019). However, some 
discrepancies have been noted, as higher XIAP 
levels was also correlated to longer overall survival 
in non-small cell lung cancer patients (Ferreira et al., 
2001b). Additionally, XIAP expression did not show 
any prognostic significance in cervical carcinoma 
(Liu et al., 2001) nor was that able to predict the 
response to chemotherapy in patients with advanced 
NSCLC (Ferreira et al., 2001a) .  
An extensive study was conducted by Hussain and 
colleagues (2017) to assess the expression of XIAP 
in over 1000 Middle Eastern breast cancer cases by 
immunohistochemistry, and found this IAP to be 
overexpressed in 29.5% of the cases with an 
association to tumor size, extra nodal extension, 
triple negative breast cancer and poorly 
differentiated breast cancer subtype (Hussain et al., 
2017). Expression and clinical significance of XIAP 
in a wide variety of cancer was further assessed and 
demonstrated in ovarian, lung, colorectal, thyroid, 
prostate, cervical, melanoma, salivary gland, 
pancreatic, cervical cancers, kidney, liver, 
neuroblastoma, oral, among others. Some of these 
will be further discussed herein.  
XIAP expression was shown to be regulated at 
multiple levels, including transcriptional, post-
transcriptional and translationally regulation. 
Transcriptional activation of XIAP may be 
controlled via NFkB pathway and ATP7A (ATPase 
copper transporting alpha) (Karin & Lin, 2002; Dai 
et al., 2005; Evans et al., 2018). XIAP protein but not 
its mRNA was found to be highly increased in 
childhood acute lymphoblastic leukemia compared 
to control bone marrow mononuclear cells, and no 
correlation between protein levels and mRNA was 
seen either, indicating post-transcriptional regulation 
(Hundsdoerfer et al., 2010). XIAP expression may 
also be regulated by an alternative translation 
initiation by a 162-nucleotide internal ribosome 
entry site (IRES) located in the 5' untranslated region 
of XIAP mRNA (Holcik et al., 1999; Holcik  
Korneluk, 2000).  
In addition, different expression levels in normal 
cells of the same lineage in different organs indicates 
that IAP expression is also influenced by cell type 
and organ-dependent regulatory mechanisms 
(Vischioni et al., 2006). Moreover, Yan and 
colleagues (2004) demonstrated a tumor stage-
dependent increase of both XIAP mRNA and protein 
expression in renal cell carcinoma (Yan et al., 2004).  
At a protein level, XIAP activity may also be 
negatively regulated by the interaction with specific 
endogenous inhibitors, i.e. DIABLO (diablo IAP-
binding mitochondrial protein), HTRA2 and XAF1 
(XIAP-associated factor-1) (Srinivasula & Ashwell., 
2008; Desplanques et al., 2009; Ye et al., 2019; 
Abbas & Larisch, 2020), or stabilized by other IAPs 
and proteins to enhance its activity (Dohi et al., 2004; 
Rajalingam et al., 2006). XIAP also forms a complex 
with SIVA1 and NR2C2 (TAK1), which inhibits 
XIAP/TAK1/ TAB1 -mediated NFκB activation, 
activates JNK activity and modulates apoptosis 
responses (Resch et al., 2009). 
Localisation 
Subcellular localization of XIAP is heterogenous, 
but it is predominantly cytoplasmic, being found in 
the nucleus also in the membrane. 
Immunofluorescence of transfected HeLa cells 
indicated that XIAP localized to the cytoplasm, 
being more prominent in the peri-nuclear region. The 
study also aimed to evaluate if co-expression of 
XIAP and XAF1 could alter its localization and 
concluded that the expression of XAF1 induced 
redistribution of XIAP from cytoplasm to nucleus 
(Liston et al., 2001).  
Germ and Sertoli cells displayed XIAP in both 
cytoplasm and nucleoli (Vischioni et al., 2006). 
Fluorescence staining of hNOKs (human normal oral 
keratinocytes) revealed XIAP to be localized mainly 
in the cytoplasm and perinuclear areas, whereas in 
Tca8113 cell line (squamous cell carcinoma of the 
human tongue) high levels of this IAP were found 
both in the cytoplasm and the nucleus (Gao et al., 
2006). In gastric cancer tissue samples, XIAP 
expression was detected exclusively in the 
cytoplasm (Dizdar et al., 2017).  
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Figure 2. XIAP (BIRC4) is a multi functional protein.  XIAP is involved in multiple cellular signaling pathways and cellular 
processes, including cell death, inflammation, cell cycle, and cell migration. The multifunctionality of XIAP is possible due to the 
different domains presented. The main function attributed to XIAP is its antiapoptotic activity, acting on intrinsic and extrinsic 
apoptotic pathways. XIAP binds and inhibits CASP9 (caspase 9) and its effectors CASP3 and CASP7 (caspase 3 and caspase 
7). XIAP also acts on caspase inhibition by ubiquitination. XIAP has also a role in the suppression of autophagy, once its 
depletion resulted in increased expression of SQSTM1 (p62), a feature induced, in fact, by prevention of the ubiquitin- 
proteasomal degradation of SQSTM1 mediated by E3 ligase activity of XIAP. XIAP has been linked to cytochrome C release, 
suggesting that XIAP may enhance mitochondrial membrane permeabilization. It was demonstrated that XIAP physically 
interacts with HSP70 and, interestingly, that the use of HSP70 inhibitors promotes down-regulation of XIAP. In addition, XIAP 
regulates TAB1/NR2C2/NFKB1 axis modulating apoptosis. 
 
XIAP displayed different patterns of localization in 
pancreas: acinar exocrine cells showed stronger 
staining in a granular supranuclear position (alike in 
glands of the small intestine and in the bronchial 
epithelium); while ductal cells presented XIAP 
diffused in the cytoplasm (Vischioni et al., 2006). A 
granular pattern in the cytoplasm had already been 
described in NSCLC cells, mainly in 
adenocarcinoma sections (Ferreira et al., 2001a; 
Ferreira et al., 2001b).  
XIAP membrane localization was described in 
endometrial glands, more prominently in brush 
border or basolateral type. The interaction of XIAP 
with bone morphogenetic protein (BMP) type I 
receptors via its RING-finger domain also suggests 
a possible localization in the plasma membrane 
(Yamaguchi et al., 1999; Vischioni et al., 2006). 
Function 
XIAP function has been widely described, 
presenting involvement in multiple cellular signaling 
pathways, including cell death, immunity, 
inflammation, cell cycle, and cell migration (Vucic, 
2018). This multiplicity of activities is partially due 
to the distinct domains present in XIAP. Still, the 
main function of this protein is the inhibition of the 
apoptosis cascade due to its binding to the initiator 
CASP9 (caspase-9), and the effector CASP3 and 
CASP7 (caspases 3 and 7), via its BIR3 and BIR2 
domains, respectively, as demonstrated in figure 2 
(Obexer and Ausserlechner, 2014) 
Another important mechanism for caspase inhibition 
by XIAP involves the E3 ligase activity of the RING 
domain, which is correlated with ubiquitination of 
XIAP-bound caspases. Thus, it can be concluded 
that XIAP interferes with extrinsic as well as 
intrinsic death pathways (Pistritto et al., 2016). Such 
ubiquitination activity may be associated with XIAP 
itself, XIAP-interacting proteins involved in 
apoptosis, and other different targets involved in 
apoptosis (Galban and Duckett, 2010). XIAP has 
also been correlated to suppression of autophagy, 
once depletion of this IAP resulted in increased 
expression of SQSTM1 (p62), a feature induced, in 
fact, by prevention of the ubiquitin-proteasomal 
degradation of SQSTM1 mediated by E3 ligase 
activity of XIAP (Huang et al., 2019).  
Another study evidenced that XIAP also localizes to 
the mitochondria, deregulating its functions, 
especially concerning cytochrome c release, 
suggesting that XIAP may enhance mitochondrial 
membrane permeabilization and control cytochrome 
c release (Chaudhary et al., 2016). Furthermore, the 
tumor suppressor protein SEPTIN4, expressed in the 
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outer mitochondrial membrane, promotes cell death 
through the antagonism of XIAP, leading XIAP to 
execute ubiquitination and degradation of BCL2 
and, consequently, apoptosis (Edison et al., 2017), 
reinforcing the role the mitochondria plays in XIAP 
homeostasis.  
Recently, it was demonstrated that XIAP physically 
interacts with HSP70 and, interestingly, that the use 
of HSP70 inhibitors promotes down-regulation of 
XIAP in both cancer cell lines and xenograft tumors 
(Cesa et al., 2017) .  
In normal development, XIAP levels and function 
were studied using XIAP-deficient mice. 
Histopathological analysis revealed no differences 
compared to wild-type mice and, moreover, no 
defects in induction of caspase-dependent or -
independent apoptosis were observed. However, 
other IAPs proteins were found to be upregulated, 
including BIRC2 and BIRC3, which suggests the 
existence of a compensatory mechanism (Harlin et 
al., 2001). Still, in cancer, high XIAP levels have 
been correlated with a poor prognosis (Cossu et al., 
2019). 
Homology 
XIAP has high homology among different species 
(Table 1).  
% Identity for: Homo 
sapiens BIRC7 
Symbol Protein DNA 
vs. P. troglodytes XIAP  98.4  98.9  
vs. C. lupus XIAP  87.4  91.1  
vs. B. taurus XIAP  87.7  91.8  
vs. M. musculus Xiap  89.5  90.1  
vs. R. norvegicus Xiap  89.9  89.8  
vs. G. gallus XIAP  59.2  66.7 
vs. X. tropicalis xiap  53.0 61.7 
vs. D. rerio xiap  51.1  55.6  
vs. A. gambiae AgaP_AGAP012677  43.0  52.1 
Table 1.  Comparative identity of human XIAP with other 
species (Source: http://www.ncbi.nlm.nih.gov/homologene) 
Mutations 
Somatic 
Recurrent mutations in the XIAP gene are rare. 
Among the 47,186 samples reported in COSMIC 
(Catalogue of Somatic Mutations in Cancer; 
http://cancer.sanger.ac.uk/cancergenome/projects/c
osmic), 182 mutations were reported in XIAP (138 
missense substitutions, 23 synonymous 
substitutions, 14 nonsense substitutions, 3 frameshift 
deletions and 2 frameshift insertions). In cBioPortal 
(http://www.cbioportal.org), among the 42,119 (159 
studies) cancer samples accessed, only 0.5% 
presented XIAP mutations (corresponding to 195 
mutations, of which 171 are missense substitutions, 
22 truncated genes and 2 other mutation). When 
mutations, amplifications, deep deletions and 
multiple alterations were considered, the total of 
cancer samples bearing any type of genetic alteration 
in XIAP was 351 (0.8%). 
Implicated in 
Bladder cancer 
XIAP, BIRC7, and BIRC5 were found to be 
simultaneously expressed in bladder cancer cells, 
with synergistic effects on cell growth and apoptosis. 
Knockdown assays targeting these three genes 
synergistically inhibited the proliferation and in vitro 
transformation ability, while also promoting 
apoptosis (Yang et al., 2010). 
XIAP levels can be considered a biomarker of 
malignancy for bladder carcinoma, once it was found 
up-regulated in urine samples from bladder 
carcinoma patients compared to samples of patients 
with non-malignant bladder diseases (Srivastava et 
al., 2015). In urinary cancer, XIAP expression was 
shown to play a key role in the maintenance of tumor 
phenotype mediating multiple pathways: XIAP 
overexpression promoted bladder cancer invasion in 
vitro and lung metastasis in vivo through activation 
of the MAPK1 / NCL/ ARHGDIB axis (Yu et al., 
2018). Also, its BIR domain regulated the EGFR 
translation by suppressing MIR200A expression and 
promoting cancer development and progression 
(Huang et al., 2017). The RING domain of XIAP 
also contributed to malignant transformation in 
bladder cancer, once it inhibited the expression of 
TP63, a known tumor suppressor, critical for the 
transformation of normal urothelial cells (Jin et al., 
2016). 
In T24 and 5637 cell lines, XIAP overexpression 
was reverted by embelin treatment that promoted a 
dose-dependent cell death mediated by the 
PI3K/AKT pathway (Fu et al., 2016). The use of 
DIABLO IAP-binding mitochondrial protein 
mimetics (UMUC-6, UMUC-12, and UMUC-18) in 
combination with typical chemotherapy drugs like 
cisplatin and gemcitabine promoted increased 
apoptosis, decreased microvessel density and 
decreased cellular proliferation that was shown to be 
related to the inhibition of IAPs, including XIAP 
(Lee et al., 2013). 
Brain cancer 
New potential therapeutic targets in glioblastomas 
were investigated by analyzing the expression and 
function of eight proteins that are known to play a 
role in cell survival and therapy resistance. The 
analysis of 50 samples from glioblastoma patients by 
immunohistochemistry revealed high expression of 
XIAP and ABCG2 (also known as BCRP, a member 
of the ABC transporters that use ATP to efflux 
endogenous small molecules and exogenous 
cytotoxic drugs) at the protein level were related to 
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poor survival (Emery et al., 2017). Another study 
evaluated the expression of anti and pro-apoptotic 
genes in 30 samples of glioblastoma patients by real-
time PCR, which found higher levels of XIAP and 
BCL2 in glioblastoma samples compared to 10 
samples from white matter control (Tirapelli et al., 
2017).  
Additionally, higher XIAP mRNA levels were found 
on CD133+ compared to CD133- adult glioblastoma 
primary cultured cells (LIU et al., 2006). Higher 
levels of XIAP were also seen in DAOY and 
D283MED cells compared to normal human 
astrocytes and immortalized fibroblasts. Moreover, 
expression of XIAP inversely correlated with that of 
CDKN1A (p21), suggesting IAPs may be involved 
in cell cycle control by CDKN1A suppression 
(CHEN et al., 2018).  
Treatment with IAP inhibitors LCL161 or LBW242 
alone or in combination with conventional 
chemotherapeutic agents, i.e. vincristine or cisplatin, 
as well as RNAi-mediated knockdown of XIAP, 
arrested the cell cycle at the G2/M phase through 
downregulation of CCNB1 - CDK1 and CCNA2 -
CDK1/ CDK2 complexes in DAOY and D283MED 
cells (Chen et al., 2018). These IAP inhibitors 
combined with chemotherapy also enhanced the 
antiproliferative effect on MB cell line through 
autophagy induction and CASP3/CASP7-activated 
apoptosis (Chen et al., 2016).  
Treatment with IAP inhibitors LCL161 or LBW242 
alone or in combination with conventional 
chemotherapeutic agents, i.e. vincristine or cisplatin, 
as well as RNAi-mediated knockdown of XIAP, 
arrested the cell cycle at the G2/M phase through 
downregulation of CCNB1-CDK1 and CCNA2-
CDK1/CDK2 complexes in DAOY and D283MED 
cells (Chen et al., 2018). These IAP inhibitors 
combined with chemotherapy also enhanced the 
antiproliferative effect on MB cell line through 
autophagy induction and CASP3/CASP7-activated 
apoptosis (Chen et al., 2016).  
In U87MG glioblastoma cells, treatment with 
isolinderalactone, a sesquiterpene found in the roots 
of L. aggregata, resulted in a significant dose-
dependent reduction of XIAP, BIRC5 and BCL2 
levels, and apoptosis induction (Hwang et al., 2019). 
Crude extracts of medicinal herbs (crude alkaloid 
extract of R. stricta and crude flavonoid extract of Z. 
officinale) decreased mRNA expression levels of 
XIAP, BIRC5 and CCND1, while expression of 
CDNK1A and PMAIP1 were upregulated in 
U251MG cell line (Elkady et al., 2014).  
XIAP and MYC expression were significantly 
decreased in 51A and SU-2 cell lines after treatment 
with HDAC6 inhibitor, resulting in decreased 
CHEK1 activity through proteasomal degradation, 
leading to radio-sensitivity and reduced DNA 
damage repair capacity of glioma stem cells, a group 
of 'stem-like' cells hardly to be completely removed, 
thus conferring resistance to radio and chemotherapy 
in glioblastoma (Yang et al, 2017). 
Breast cancer 
IAPs were shown to be overexpressed in various 
numbers of cancers, including breast cancer and 
were associated with a poor prognosis and drug 
resistance (Moraes et al., 2015, Huang et al., 2018), 
making them an interesting target for therapy. In 
immunohistochemical experiments, it was shown 
that XIAP positively stained the majority of breast 
cancer cells with moderate or strong intensity 
(Zohny; Zamzami; El-Shinawi, 2018).  
In another study, it was found that in one third of 
breast cancer patients presented XIAP 
overexpression, which was associated with a 
reduced overall survival (Hussain et al., 2017).  
In a study with inflammatory breast cancer (IBC) 
was noticed that XIAP was also overexpressed in 
IBC patient tumors and high-grade breast cancers, 
corroborating XIAP overexpression in breast cancer 
(Evans et al., 2018).   
Additionally, high XIAP expression was associated 
with reduced CASP3 activation and apoptosis rates 
in breast cancer tumors compared to benign breast 
lesions.  
In immunoreactivity studies using breast cancer 
samples, high XIAP expression was found, but it did 
not correlate with age, tumor size, grade, status of 
lymph node, expression of ESR1 (estrogen receptor) 
and PGR (progesterone receptor). In addition, XIAP 
expression was found in 80% of patients with triple-
negative invasive ductal breast cancer and it was 
related with primary tumor size and reduced disease-
free survival and overall survival (Zohny; Zamzami; 
El-Shinawi, 2018). 
Cervical carcinoma 
Immunohistochemistry analysis of 15 cases of 
normal cervical tissues, 69 cases of cervical 
intraepithelial neoplasia (CIN) and 76 cases of 
cervical carcinoma revealed increased expression of 
XIAP in tumor than normal tissues, inversely 
associated with diablo (Smac) expression. In the 
same study, XIAP expression was associated with 
pelvic lymph node metastasis (Jin et al., 2017). A 
semi quantitative RT-PCR analysis of 6 normal and 
41 cancer tissues, including 8 stage I cases, 16 stage 
II and 17 stage III revealed no differences in the 
expression of XIAP between normal and tumor 
samples. However, an unexpected positive 
association between low levels of XIAP and disease 
relapse was observed, and an inverse relation 
between XIAP expression and tumor aggressiveness 
(Espinosa et al., 2006).  
The crude extract of the Chinese herb Antrodia 
camphorata induced apoptosis in HeLa and C-33A 
cells, showing a decrease in the expression of XIAP 
among other anti-apoptotic proteins (Yang et al., 
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2013). Xanthohumol, a prenylated chalcone isolated 
from Humulus lupus, also downregulated expression 
of anti-apoptotic proteins such as XIAP in Ca Ski 
cervical cancer cell line, inhibiting proliferation 
(Yong et al., 2015). 
Colorectal cancer 
XIAP mRNA expression was shown to be 
upregulated in a study comparing 100 cancer to 100 
normal tissues from patients with sporadic colorectal 
cancer by real time PCR, of which half were KRAS 
wild-type and the other half KRAS mutant (Devetzi 
et al., 2016). XIAP was also shown to be upregulated 
while pro-apoptotic BAX and BID were 
downregulated in HT-29 cells resistant to 5-FU 
compared to wild type (Manoochehri et al., 2014). In 
contrast, the expression of XIAP and other IAPs, 
except BIRC3, did not show significant differences 
in the normal mucosa of patients with advanced 
colorectal adenoma (Choi et al., 2017).  
The diablo IAP-binding mitochondrial protein 
mimetic BV6, reduced cellular levels of XIAP, re-
sensitizing BAX-deficient HCT-116, wildtype HCT-
116, HCT-8 and DLD1 cells grown under hypoxic 
conditions to TNFSF10 and/or FASLG (CD95L) -
induced cell death (Knoll et al., 2016). In addition, 
XIAP-deficient HCT-116 cells showed significant 
less TRAIL resistance under hypoxia compared to 
HCT-116 wild type cells (Knoll et a., 2016). BV6 
also substantially increased 3D radiation response of 
HCT-15, HT-29 and SW480 cells upon BIRC2 and 
XIAP degradation, resulting in enhanced irradiation-
induced apoptosis and DNA double-strand break 
repair hampering (Hehlgans et al., 2015). Agreeing 
with this, combinatorial treatments with TNFSF10 
and Smac mimetics or XIAP-targeting drugs were 
reported to overcome hypoxia-induced TNFSF10 
resistance, demonstrating that a reasonable 
alternative was to target XIAP as well as TNFSF10 
in order to obtain stronger responses (Knoll et al., 
2016).  
Upregulation of XIAP might also be responsible for 
the acquired resistance to oxaliplatin, as established 
oxaliplatin-resistant SW480 and HT29 cells were 
shown to express significantly higher levels of XIAP 
and lower levels of MIR122 compared to wild types. 
A recovery of miR-122 expression was able to 
sensitize these colorectal cancer cells to oxaliplatin-
mediated apoptosis through inhibition of XIAP 
expression. Thus, XIAP may offer a good strategy 
for reducing oxaliplatin resistance in colorectal 
cancer (Hua et al., 2018).  
Transcriptomic analysis revealed that 
propionibacterial supernatant or its metabolites 
(propionate and acetate) increased pro-apoptotic 
gene expression (TNFSF10) and reduced anti-
apoptotic gene expression of CFLAR and XIAP 
when administered in combination with TNFSF10 in 
HT-29 cells (Cousin et al., 2016).  
In HT29 cells, mithramycin A selectively 
downregulated XIAP through inhibition of SP1 
binding to its promoter.  
Suppression of XIAP transcription, by siRNA, 
enhanced TNFSF10-induced apoptosis even though 
its overexpression significantly attenuated apoptosis 
induced by MithA plus TNFSF10, indicating a 
critical role for XIAP in the recovery of TRAIL 
sensitivity in various cancer cells (Lee et al., 2006).  
Impaired CASP3 maturation by XIAP was also 
identified as one of the underlying mechanisms 
relating XIAP to TNFSF10 resistance in HCT-116 
PIK3CA -mutant cells, as TNFSF10 sensitivity was 
efficiently restored after XIAP or proteasome 
inhibition, indicating that targeting XIAP or the 
proteasome in cells with PIK3CA mutations, which 
are found in 10-20% of colorectal tumors, may 
represent a good therapeutic strategy concerning 
TNFSF10 (Ehrenschwender et al., 2014).  
COLO 205 and HCT-116 cells transfected with 
shRNA targeting AKAP4 (A-kinase anchor protein 
4) resulted in XIAP downregulation among other 
anti-apoptotic molecules, while pro-apoptotic 
molecules were upregulated (Jagadish et al., 2015). 
TGFB1 / PRKACB (PKA) / PP2A signaling 
deactivated AKT phosphorylation leading to 
downregulation of XIAP and BIRC5 in FET cell line 
(Chowdhury et al., 2011 A; Chowdhury et al., 2011 
B).  
Bufalin, a steroid-related molecule, in association 
with 5-fluorouracil reduced the expression of XIAP 
and other IAPs, while elevated the expression of pro-
apoptotic proteins (Dai et al., 2018).  
Moreover, MK-2206, an allosteric kinase inhibitor 
of AKT, dephosphorylated EZR (ezrin) at the T567 
site and led to disruption of AKT-EZR-XIAP cell 
survival signaling (Agarwal et al., 2014). 
Phosphorylation of EZR at the T567 site was 
regulated by the IGF1R signaling pathway, and such 
activation enhanced cell survival in colorectal cancer 
cells by modulating XIAP and BIRC5 in both 
orthotopically implanted GEO tumors, as well as, 
human patient specimens (Leiphrakpam et al., 
2014).  
SATB2 (special AT-rich binding protein-2) 
overexpression resulted in upregulation of XIAP and 
CCND1 in CRL-1831 cells (Yu et al., 2017). 
Silencing PIK3CA (PI3K p110α), by siRNA, also 
resulted in alterations in the expression of XIAP in 
KRAS/PIK3CA-mutant HCT-116 (Fernandes et al., 
2016).  
Placet et al. (2018) suggested that P2RY6 receptor 
could be targeted to block XIAP activity in 
colorectal cancer. P2RY6 stimulation with its 
selective agonist MRS2693 induced XIAP 
phosphorylation on Ser87 residue, concomitant to 
phosphorylation of AKT Thr3008 residue, and it was 
correlated to XIAP increase and maintenance over 
time. These findings suggested that P2Y6R 






Atlas Genet Cytogenet Oncol Haematol. 2020; 24(11) 431 
 
antagonists could be used to block XIAP activity and 
enhance the therapeutic effect of drugs such as 5-
fluorouracil (Placet et al., 2018). 
Esophageal cancer 
Immunohistochemistry analysis of 120 esophageal 
squamous cell carcinoma (ESCC) and 90 esophageal 
adenocarcinoma (EAC) tissues with their 
corresponding normal mucosa samples revealed 
high expression levels of XIAP in tumor tissues. The 
same study identified XIAP as an independent 
negative prognostic marker in ESCC (Dizdar et al., 
2018). Another study using immunohistochemistry 
of 78 ESCC patients treated with radiotherapy after 
surgery revealed increased XIAP expression and it 
was correlated with tumor differentiation and TNM 
stage (Zhou et al., 2013). Schiffmann and colleagues 
also reported XIAP expression might serve as a tool 
to improve outcome prediction and identify high-risk 
patients, whom may be a candidate for a more 
aggressive therapy strategy (Schiffmann et al., 
2019). Additionally, 170 ESCC patients and 191 
healthy people were genotyped and related 
polymorphisms rs8371 and rs9856 with 
susceptibility to ESCC, and rs8371 polymorphism 
might serve as an indicator improved clinical 
efficacy and prognosis (Peng et al., 2017) .  
Treatment of five ESCC cell lines with TNF 
combined to cycloheximide (CHX) induced 
significant apoptosis and decreased expression of 
XIAP and BIRC2. This effect was not seen when 
cells were treated with either TNF or CHX alone, but 
XIAP or BIRC2 siRNA transfected cells underwent 
apoptosis when TNF was administered alone, a 
result that was further increased by double 
knockdown, suggesting XIAP along with BIRC2 
might play an essential role in apoptosis-resistance 
of ESCC cells (Hikami et al., 2017).  
Esophageal cancer cells treated with siRNA 
targeting XIAP in combination to radiotherapy 
presented decreased cell survival rate and colony 
forming efficiency. Besides, nude mice treated with 
siRNA had a decrease in tumor weight and volume 
compared to control group, indicating that XIAP 
gene silencing could be an allied in radiotherapy 
strategies for esophageal cancer (Wen et al., 2017). 
Treatment with siRNA targeting XAIP also 
enhanced chemosensitivity of ESCC cells, as seen in 
a study that combined this strategy with paclitaxel, 
cisplatin, 5-fluorouracil and etoposide (Zhang et al., 
2007). 
Gastric cancer 
An analysis for expression of IAPs in over 1,100 
surgically resected gastric cancer (GC) tissue 
specimens revealed XIAP was present in 20% of the 
cases, whereas XIAP inhibitors, such as XAF1 and 
diablo IAP-binding mitochondrial protein, were seen 
in 76.6% and 13.9% of cases respectively. XIAP 
expression was strongly related to advanced stage. In 
the same study, high expression of XIAP was also 
related to decreased patient survival rates, indicating 
this as an independent prognostic factor for poor 
survival outcomes (Kim et al., 2011). Another study 
considering 144 patients also found that XIAP 
expression levels were significantly related to tumor 
size, serosal invasion and lymph node metastasis. 
The authors further demonstrated that XIAP 
expression was significantly elevated in HGC-27 
and MGC803 gastric cancer cell lines compared to 
GES-1 normal gastric epithelial cells (Li et al., 
2018). In addition, among other eight proteins, XIAP 
was seen to be upregulated in AFP (alpha-
fetoprotein) producing gastric adenocarcinoma, and 
its overexpression was correlated to poor relapse-
free survival and overall survival, but not in the AFP 
non-producing patients (He et al., 2016).  
XIAP and BIRC5 levels were evaluated in 201 
patients who underwent total or subtotal gastrectomy 
and extended (D2) lymphadenectomy. High levels of 
both IAPs were seen in gastric cancer tissue 
specimens when compared with normal mucosa and 
were correlated with an intestinal-type and well-
differentiated gastric cancer, as also to low UICC 
stages. High levels of XIAP was detected in lymph 
node metastasis compared to corresponding primary 
tumors, which supports the hypothesis that it also 
plays an important role in metastatic tumors. XIAP 
overexpression was identified as an independent 
negative prognostic marker in diffuse and mixed 
type of gastric cancer. Tissue microarray revealed 
XIAP was present only in the cytoplasm, whereas 
BIRC5 was found in both the nucleus and the 
cytoplasm. The authors also identified a positive 
correlation between cytoplasmic BIRC5 and XIAP 
expression (Dizdar et al., 2017).  
XIAP was downregulated after treatment with 
cycloheximide (CHX) and the effect was enhanced 
when combined CHX to TNF, resulting in induced 
apoptosis that may occur by accelerated proteasome-
mediated degradation of XIAP and other IAP family 
members in addition to inhibition of NFKB1-
dependent synthesis of anti-apoptotic molecules 
(Kitagawa et al., 2015).  
Treatment with L-asparaginase in human gastric  
adenocarcinoma cells (AGS) significantly down-
regulated anti-apoptotic genes i.e. XIAP, BID, 
MCL1, and death receptors TNF and TRADD, while 
pro-apoptosis genes i.e. BAK1, BAX, BIK, APAF1, 
CASP3, CASP7, and CASP9 were upregulated. 
Further analysis confirmed intrinsic apoptosis 
pathway activation (Sindhu et al., 2018). Treatment 
with H72, a synthetic brominated chalcone 
derivative, reduced protein levels of XIAP, 
BCL2L1, and BIRC5, while increased levels of 
BCL2L11 BIM, TNFRSF10A (DR4), and 
TNFRSF10B (DR5), with no changes in BAX levels 
in MGC803 cells (Zhang et al., 2016).  
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Furthermore, scutellarein, a flavone glycoside 
obtained by hydrolysis of scutellarin found in herbs 
from Scutellaria genus, induced apoptosis and 
inhibited cell proliferation via down regulation of 
MDM2, which activates the tumor suppressor 
protein TP53, leading to down regulation of XIAP, 
BIRC2 and BIRC3 in a dose-dependent manner in 
AGS and SNU-484 gastric cancer cells (Gowda 
Saralamma et al., 2017). CDK7 selective inhibition 
by BS-181, a pyrimidine-derived compound, 
induced apoptosis due to a significant decrease in 
XIAP and CCND1 expression in BGC823 cells 
(Wang et al., 2016).  
A double knockdown of both XIAP and BIRC5 
expression by siRNA resulted in a notable increase 
in apoptosis rates and suppression of cell 
proliferation compared to cells submitted to a single 
knockdown of either BIRC5 or XIAP (Li et al., 
2018).  
XIAP levels were inversely correlated to expression 
of MIR509-3p in tissue specimens collected from 
patients with gastric cancer, which was a clinically 
significant miRNA detected in higher abundancy in 
patients with favorable survival states, both in The 
Cancer Genome Atlas and in an independent cohort 
(Pan et al., 2016). Paired tissues revealed significant 
downregulation of miR-509-3p in tumor tissues, and 
such downregulation was strongly correlated to poor 
outcomes (Sun et al., 2017). 
Head and neck squamous cell 
carcinoma 
Immunohistochemistry assays revealed XIAP 
expression in 40 of out 59 sections from routinely 
processed specimens of head and neck squamous 
cell carcinoma (HNSCC), in which staining varied 
from weak or focal to strong or diffuse (Nagi et al., 
2007).  
XIAP expression was found in 17 out of 60 samples 
accessed, which was associated with cisplatin 
resistance and poor clinical outcome in advanced 
HNSCC patients. Chemotherapy with cisplatin 
induced XIAP expression. In HNSCC cells, cisplatin 
sensibility was significantly increased after 
inhibition of XIAP by siRNA. Along with alcohol 
consumption and lymph node metastasis, XIAP was 
found to be an independent prognostic marker of 
advanced HNSCC patients (Yang et al., 2012). 
Moreover, Yang and other colleagues (2018) 
reported that patients with HNSCC co-expressing 
high levels of XIAP and BIRC2 had shorter overall 
and disease-free survival compared to patients 
expressing low levels of both IAPs, indicating a 
synergistic effect of these proteins on prognosis 
(Yang et al., 2018).  
Depletion of XIAP, by shRNA, significantly 
enhanced cell death after treatment with TNFSF10 
combined to bortezomib in UPCI:SCC089 and 
UPCI:SCC090 cell lines (Bullenkamp et al., 2014). 
Kidney cancer 
XIAP expression was upregulated and associated 
with poor prognosis in kidney cancer patients 
(Mizutani et al., 2007; Bilimet al., 2008). It was also 
shown that the decrease in the expression of XIAP 
by antisense oligonucleotide enhanced sensibility of 
renal cell carcinoma cells to FAS/ TNFSF10-
mediated cytotoxicity (MizutaniI et al., 2007). In 
renal cell carcinoma, XIAP expression increased 
from early (pT1) to advanced tumor stages (pT3), 
similarly to dedifferentiation stages and tumor 
aggressiveness (Yan et al., 2004; Ramp et al., 2004). 
Among the different histological renal cell 
carcinomas, it was observed that the clear cell type, 
that has a poor diagnosis, had a higher XIAP 
expression than the papillary (Yan et al., 2004). In 
addition, XIAP expression was found in 137 of 145 
(95%) of the investigated clear cell renal cell 
carcinoma, a tumor of the kidney that accounts 70% 
of all renal cell carcinoma. 
Leukemia 
Leukemia cells appear to have anti-apoptotic 
proteins in order to survive under hostile conditions 
(Walsby et al., 2013), and studies have shown that 
these molecules may be useful as prognostic markers 
(Tamm, 2004). XIAP was frequently overexpressed 
in leukemia cells, serving as regulators in the cell 
survival (Hu et al., 2014).  
In a panel made purposely for the study of the 
relation of IAPs and leukemia containing 60 human 
tumor cell lines showed, among acute myeloid 
leukemia (AML) blasts derived from newly 
diagnosed patients, that patients with low levels of 
XIAP had a longer survival rate and were inclined to 
a longer median remission duration. This finding 
implied that XIAP has a potential prognostic value 
in AML (Tamm et al., 2000). In adult acute myeloid 
leukemia (AML), XIAP expression was lower in 
AML cells with granulocytic differentiation when 
compared to myelomonocytic-differentiated cells, 
which suggests that XIAP plays a role in normal 
monocytic and malignant differentiation. Supporting 
this finding, downregulation of XIAP blocks 
monocytic differentiation induced by bryostatin 1 in 
leukemia cells (Tamm, 2004).  
One of the most well-known XIAP inhibitor is 
embelin, a cell-permeable and small molecule that 
inhibits XIAP through DIABLO IAP-binding 
mitochondrial protein. Embelin was shown to 
promote downregulation of XIAP and release of 
CASP9, which normally initiates caspase cascades 
and leads to apoptosis. Furthermore, embelin 
induces apoptosis in leukemia cell line HL60 by 
XIAP downregulation (Hu et al., 2014). 
Additionally, it was demonstrated that low-toxicity 
embelin sensitization of HL60 cells to TNFSF10 -
induced apoptosis was not intimately related to 
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XIAP inhibition, showing that low-toxicity embelin 
alone or jointly with TNFSF10 did not change the 
expression of XIAP (Hu et al., 2014). There are other 
molecules proposed as XIAP inhibitors, including 
CDKI-73, which also inhibited MCL1, BCL2, 
CCND1 and CCND2 (Walsby et al., 2013), and 
nilotinib, which was shown to inhibit the expression 
of XIAP in two MDM2-overexpressing cell lines, 
suggesting that nilotinib-mediated XIAP inhibition 
was dependent of MDM2, since this was not 
observed for MDM2-negative cell line (Zhang et al., 
2014). In leukemia cells, the co-treatment with 
SAHA and S116836 repressed anti-apoptotic 
proteins, including XIAP (Bu et al., 2014).  
Natural products were also studied regarding its 
effects on XIAP inhibition, for instance, AVO (an 
essential oil from Artemisia vulgaris L) decreased 
the expression of XIAP leading to inhibition of the 
activation of caspases 9 and 3 in HL60 leukemia 
cells (Saleh et al., 2014). 
Liver cancer 
In hepatocellular carcinoma patients, XIAP 
expression was associated with poor overall survival 
and, in cell lines, was shown to play an important 
role in modulating cell apoptosis and cell cycle 
progression through regulation of CDK4, CDK6 and 
CCND1 via NFKB1 and PTEN pathways (Che et al., 
2012). Treatment of hepatocellular carcinoma cells 
with embelin resulted in increased apoptosis and 
decreased cell proliferation via an arrest at the G1 
phase (Che et al., 2012). In contrast, it was observed 
that apoptosis resistance may be related to a 
significantly lower expression of XAF1, but not 
XIAP in poorly differentiated hepatocellular 
carcinoma tissues (Sakemi et al., 2007). Zhu and 
colleagues reported lower levels of XAF1 expression 
in SMMC-7721, HepG2 and BEL-7404 cell lines, as 
well as in liver cancer tissues compared to their 
paired non-cancer hepatic tissues. Adenovirus-
mediated XAF1 expression (Ad5/F35-XAF1) 
significantly inhibited cell proliferation and induced 
apoptosis, while significantly suppressed xenograft 
tumor growth of hepatocarcinoma cells (Zhu et al., 
2014).  
XIAP was also associated with therapeutic resistance 
to the histone deacetylase (HDAC) inhibitor JNJ-
2648158, which induced the transcription of XIAP 
through AP1 expression activation, conferring 
resistance to apoptosis (Wang et al., 2018). 
Moreover, Winkler and colleagues (2014) reported 
XIAP to play an important role in the pro-survival 
function of the exportin cellular apoptosis 
susceptibility (CAS) in hepatocellular carcinoma 
models (Winkler et al., 2014).  
Cisplatin treatment downregulated XIAP 
expression, while XIAP knockdown by siRNA 
enhanced the pro-apoptotic effects of cisplatin in 
LM3 cell line (Shang et al., 2018). A fraction of the 
natural extract derived from Artemisia capillaris 
obtained in ethyl acetate displayed growth and 
proliferation inhibition, induced apoptosis, increased 
levels of cleaved caspase-3 and decreased XIAP, 
BIRC5, and MCL1 expression in HepG2 and Huh7 
cell lines (Yan et al., 2018). 
Lung cancer 
In a study of the protein signature for non-small cell 
lung cancer (NSCLC) prognosis, XIAP was 
differentially expressed between NSCLC and benign 
lung tumor, indicating that XIAP is a potential 
biomarker for malignancy in lung tumors. Along 
with other proteins, XIAP was also correlated to 
invasion and lymph node metastasis, as well as 
squamous differentiation (Liu et al., 2014). In 
agreement, Huang and coworkers (2015), reported 
high levels of XIAP in lung cancer tissues compared 
to adjacent tissues samples (Huang et al., 2015).  
In contrast, Moravcikova et al. (2014) indicated that 
XIAP was not an effective suppressor of the 
apoptosome apparatus activity in NSCLC cells, 
suggesting that apoptosome-generated caspase-3 
activity can overcome the potential caspase 
inhibitory effect of XIAP.  
Baykara and colleagues (2013) also investigated the 
relation of XIAP with clinical parameters in NSCLC. 
XIAP levels were determined by ELISA in samples 
from 34 NSCLC patients and 44 healthy individuals, 
but no correlation between serum XIAP levels and 
response to chemotherapy, progression free-survival 
or overall survival were found (Baykara et al., 2013). 
Kang and colleagues (2008) performed an evaluation 
of the association between XIAP polymorphisms 
and the risk for lung cancer. The authors identified 
12 SNPs and selected 4 of them for large-scale 
genotyping based on their frequencies and haplotype 
tagging status, but no evidence of relation of XIAP 
polymorphisms with the risk of lung cancer was 
observed (Kang et al., 2008).  
XIAP-mediated ERK activation upregulated NCL 
(nucleolin) expression, which was able to stabilize 
ARHGDIB mRNA and mediate lung metastatic (Yu 
et al., 2018). In lung cancer cells, XIAP inhibited 
mature SMAC-induced apoptosis by degrading it 
through ubiquitination (Qin et al., 2016).  
Combined treatment of lambetianic acid (LA) and 
TRAIL displayed significantly decreased 
antiapoptotic proteins such as XIAP, while also 
disrupting its binding with CASP3 or NFKB1, 
enhancing TNFSF10-induced apoptosis (Ahn et al., 
2018). 
Lymphoma 
Mantle cell lymphoma, a poor prognosis and 
metastatic-related non-Hodgkin B-cell malignancy, 
presented overexpression of IAPs, including XIAP. 
In mantle lymphoma cells, B-PAC-1, a procaspase 
activating compound, induced apoptosis by the 
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sequester of Zn bound to procaspase- 3, (Sarkar et 
al., 2015) or when analyzing the anti-tumor 
properties of puerarin (Gan Yin, 2014).  
Similar to findings in mantle cell lymphoma, XIAP 
protein was upregulated in other lymphomas, such as 
Burkitt's lymphoma, a highly aggressive type of non- 
Hodgkin B-cell lymphoma (Aaqarni et al., 2018). In 
lymphoma cells, antitumor properties of indole-3-
carbinol was related to XIAP downregulation 
(Perez-Chacon; Rios; Zapata, 2014). In B-cell 
lymphomas, XIAP was overexpressed and 
associated with chemoresistance and shorter survival 
outcomes. Double knockdown of XIAP and USP9X 
delayed lymphoma development, corroborating 
XIAP as a target in lymphoma (Engel et al., 2016). 
Medulloblastoma 
XIAP was shown to be upregulated in 
medulloblastoma cells, while XIAP inhibitors 
reduced cell proliferation and induced cell death. In 
fact, this effect was also seen in the subpopulation 
CD133+ stem-like medulloblastoma cells, for which 
XIAP expression displayed even higher levels. In 
agreement, XIAP expression in cytoplasm was 
found in 75% of the medulloblastoma tissues 
compared with no expression in normal brain tissues 
(Chen et al., 2016). Inhibition of XIAP, BIRC2 or 
BIRC3 combined with conventional chemotherapy 
resulted in cell cycle arrest at G2/M phase in 
medulloblastoma cells (Chen et al., 2018). These 
findings indicated that XIAP was a potential 
diagnostic marker and therapeutic target in 
medulloblastoma. 
Melanoma 
In melanoma, the machinery behind the high 
resistance may be related to overexpression of 
proteins of the IAP family, including XIAP (Hiscutt 
et al., 2010; Mohana-Kumaran et al., 2014). XIAP 
was associated with cell growth, tumorigenesis, 
metastasis as well as progression in melanoma cells 
(Li; Ke; Wang, 2012), and it was shown to be 
overexpressed in primary cutaneous and metastatic 
melanoma tissues (Hiscutt et al., 2010). In a study 
where XIAP expression was investigated in 55 
samples of clinical patients and where samples 
consisted mainly of superficial spreading melanoma, 
XIAP expression was found to be higher in late stage 
primary cutaneous melanoma. There was also a 
significant difference on the percentage of cells 
positive for XIAP in sample obtained from patients 
that were stage II melanoma and benign nevi. When 
analyzing the range of thickness of primary tumors, 
the increase on XIAP expression was associated with 
a greater Breslow thickness (Tian; Lee, 2010). In 
another study, XIAP expression was also higher on 
thick cutaneous melanoma than when compared to 
thin ones (Emanuel et al., 2008). 
Multiple myeloma 
Multiple myeloma cells exhibited high levels of 
XIAP protein, which was associated with myeloma-
related growth factors. In the same study, XIAP 
silencing by RNAi increased drug sensitivity in in 
vitro assays and reduced in vivo tumor formation. 
Multiple myeloma cells also expressed XAF1, which 
antagonizes the caspase inhibitor function of XIAP 
(Desplanques et al., 2009). 
Neuroblastoma 
In neuroblastoma patients, XIAP was found in 18 
among the 19 cases analyzed, and the level of XIAP 
was higher within patients that had no bone marrow 
metastasis. XIAP expression was also higher in 
patients with favorable histology regardless of bone 
marrow status. XIAP expression had no significant 
difference on tumors with undifferentiated/poorly 
differentiated histology compared to differentiating 
subtypes (Osman et al., 2013). Post transcriptional 
and transcriptional mechanisms were related with 
high XIAP expression, which had been targeted by 
diablo IAP-binding mitochondrial protein mimetic 
LBW242 in neuroblastoma. Using microarray 
analysis, XIAP mRNA was associated with risk of 
relapse in a cohort of 101 neuroblastoma patients 
(Eschenburg et al., 2012). In paired neuroblastoma 
cell lines obtained from a primary tumor of a female 
patient pre- and post-chemotherapy (CHLA-15 and 
CHLA-20), XIAP was highly expressed in CHLA-
20 cells, which had undergone an intensive treatment 
with cyclophosphamide, doxorubicin, cisplatin and 
teniposide (Frommann et al., 2018). 
Oral cancer 
Using tissue microarray, high XIAP expression was 
associated with a significant reduction in overall 
survival in a cohort of 193 squamous cell carcinomas 
(Frohwitter et al., 2017). HSC-3 cells treated with 
ursodeoxycholic acid (UDCA) and Ca9-22 cells 
treated with furano-1,2-naphthoquino (FNQ) and 
PP2 (a Src-specific inhibitor) presented XIAP 
downregulation (Lin et al., 2014; Pang et al., 2015). 
Osteosarcoma 
Qu and colleagues reported that XIAP mRNA and 
protein levels were increased in osteosarcoma 
compared to adjacent non-tumoral tissues in a cohort 
of 60 tissues from osteosarcoma patients using 
quantitative PCR and immunohistochemistry 
analysis. The authors also correlated higher 
expression of XIAP to advanced clinical stage, larger 
tumor size and metastasis compared to patients 
expressing lower levels of XIAP. Using MG63 
cellular model, a shRNA targeting XIAP efficiently 
decreased cell proliferation and colony formation, 
induced apoptosis and cell cycle arrest at G0/G1 
phase, displayed enhanced chemosensitivity in 
combination with doxorubicin or cisplatin, and 
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inhibited tumor growth in nude mice (Qu et al., 
2015).  
Treatment with an aqueous plus a triterpene extract 
of Viscum album L. led to strong inhibition of 
proliferation and apoptosis, and enhanced sensitivity 
to doxorubicin, etoposide and ifosfamide in 143B 
and Saos-2 cell lines, which were associated with 
downregulation of XIAP, BIRC5 and CLSPN 
(Kleinsimon et al., 2017). In addition, the 
carotenoids fucoxanthin and its metabolite 
fucoxanthinol induced apoptosis and cell cycle arrest 
at G1 phase in osteosarcoma human and mouse cell 
lines by reducing expression of XIAP, BIRC5, 
BCL2, BCL2L1, CDK4, CDK6, and CCNE1 
(Rokkaku et al., 2013). 
Ovarian cancer 
In ovarian cancer models, proteomic analysis 
demonstrated that XIAP had a positive coefficient 
correlation with IC50 values, indicating a role for 
XIAP in drug resistance (Zervantonakis et al., 2017). 
In agreement, high XIAP levels were inversely 
correlated with carboplatin response and 
progression-free survival in patients with ovarian 
cancer (Zhang et al., 2018). It was also reported that 
ADPRH, a tumor suppressor gene, was 
downregulated in 60% of ovarian cancers and 
promoted upregulation of antiapoptotic proteins, 
including XIAP (Washington et al., 2015).  
In ovarian carcinoma cell lines, treatment with 
phenoxodiol promoted downregulation of XIAP, 
inhibited autophagy, as evidenced by decreased 
levels of ATG7, ATG12 and BECN1, and increased 
cisplatin sensitivity (Miyamoto et al., 2018). 
Treatment with 10-chlorocanthin-6-one, a cytotoxic 
agent against HO8910PM cell line, induces 
apoptosis through activation of PARP1 and caspase-
3 cleavage, upregulation of BCL2, and 
downregulation of XIAP, BIM and BIRC5 (Li et al., 
2018). MK-0752, a γ-secretase inhibitor, induced 
cell growth inhibition through downregulation of 
XIAP in a dose- and time-dependent manner (Chen 
et al., 2016).  
Natural product butein, a polyphenol widely 
biosynthesized in plants, promoted downregulation 
of XIAP, BIRC5, BIRC2, and BIRC3 in ovarian 
cancer cell lines (Yang et al., 2015). Another natural 
product, an extract of Smilax china L. rhizome, 
reduced cell proliferation in a dose-dependent 
manner and induced apoptosis by activation of 
caspase-3, PARP1 and BAX and by inhibition of 
NFκB, BCL2, BCL2L1, BIRC2, XIAP and AKT in 
A2780 cells (Hu et al., 2015). Combined treatment 
with cisplatin and biothionol enhanced apoptosis 
through the downregulation of pro-survival factors 
(XIAP, BCL2 and BCL2L1) in ovarian cancer cell 
lines (Ayyagari et al., 2017). Similarly, 1-
phenylpropadienyl phosphine oxide (PHPO) alone 
or combined with cisplatin inhibited the PI3K/AKT, 
MAPK and ATM / CHEK2 (CHK2) pathways, 
followed by suppression of the antiapoptotic factors 
BCL2L1, BCL2, and XIAP (Li et al., 2016).  
Inhibition of NFKB1 and BIRC6-XIAP complex 
induced by 10H-3,6-diazaphenothiazine treatment 
reduced metastasis capacity of A2780 cancer cell 
line (Zhang et al., 2017). In SKOV3/DDP cells, 
inhibition of NFKB1 and reduced levels of XIAP 
was also observed after treatment with noscapine, a 
non-toxic benzylisoquinoline alkaloid extracted 
from opium (Shen et al., 2015).  
The regulation of XIAP mediated by miRNAs has 
been addressed and multiple miRNAs can regulate 
XIAP via its 3'UTR. For instance, MIR137 
sensitized ovarian cancer cells to cisplatin-induced 
apoptosis via XIAP downregulation in SKOV3 cells 
(Li et al., 2017). Similar results were observed for 
MIR155 that mediated cisplatin-induced apoptosis 
by targeting XIAP (Chen et al., 2016), and for 
MIR509-3p that can directly target XIAP via its 
3'UTR in ovarian cancer cells leading to the 
inhibition of cell proliferation and increased 
sensitivity to cisplatin-induced apoptosis (Chen et 
al., 2016). In addition, it was demonstrated that 
MIR146A?5p regulated three important 
antiapoptotic genes, including XIAP, BCL2L2 and 
BIRC5 via their 3'UTRs. Decreased levels of 
MIR146A?5p led to increased IC50 values for 
cisplatin in OVCAR3 and SKOV3 cells (Li et al., 
2017). The MIR149 (which also targets XIAP) was 
significantly downregulated in ovarian cancer 
tissues and cell lines, for which expression was 
correlated with patient prognosis and cisplatin 
chemoresistance (Sun et al., 2018). The 
downregulation of MIR215 increased cell 
proliferation, inhibited apoptosis and decreased 
sensitivity to chemotherapy drugs in ovarian cancer 
cells through the elevated expression of XIAP (Ge et 
al., 2016).  
Extracellular matrix components have been 
addressed as one factor involved in chemoresistance 
in ovarian cells. The collagen COL11A1 was 
demonstrated to activate the signaling pathway 
SRC/PI3K/AKT/NFκB to induce the expression of 
three IAPs, including XIAP, which was correlated to 
the inhibition of cisplatin-induced apoptosis in 
ovarian cancer cells (Rada et al., 2018). 
Pancreatic Cancer 
XIAP was considered one of the most important 
factors in chemoresistance of pancreatic carcinoma, 
and its inhibition increased sensitivity to 5-
fluorouracil (5-FU). In pancreatic carcinoma cell 
line SW1990, XIAP upregulation was observed in 
cells exposed to 5-FU for up to 30 days. Combined 
treatment of 5-FU and gemcitabine greatly increased 
apoptosis index when XIAP was inhibited (LI et al, 
2006). High XIAP expression was also associated 
with poor outcomes in pancreatic carcinoma 
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patients, being an independent predictor and 
associated with tumor invasion status and 
histological grading (LI et al., 2013).  
The treatment with 7-benzylidenenaltrexone maleate 
(BNTX) combined to TRAIL downregulated XIAP 
expression, promoting the release of cytochrome c 
from mitochondria with caspase activation (KIM et 
al., 2017). The authors suggested that the IAP-
mediated resistance of pancreatic cancer cells could 
be overcome by PKCα/AKT pathway inhibition.  
A small-molecule IAP antagonist, AT406, 
significantly inhibited cell survival and proliferation 
in Panc-1 and Mia-PaCa-2 cell lines, and in primary 
human pancreatic cancer cells, while displayed no 
cytotoxicity to pancreatic epithelial cells. Authors 
noted a degradation of IAP family members (such as 
XIAP and BIRC2), a release of cytochrome c and 
higher activity of CASP3 and CASP9 (JIANG et al., 
2016). 
Prostate cancer 
The expression of XIAPs in normal human prostate 
(NP), benign prostatic hyperplasia (BPH), prostatic 
intraepithelial neoplasia (PIN) and prostatic 
carcinoma (PC) was evaluated and showed a 20% 
expression among NPs, 27.27% in BPHs, 33.33% in 
high-grade PIN and varying from 17.39 to 39.21% in 
PC. The latter two did not present Gleason variation 
(Rodriguez-Barriguete et al., 2015).  
Through immunohistochemical techniques, XIAP 
expression was seen on human prostate tissue 
samples, being observed in normal and malignant 
epithelium, basal cells, but not commonly on stromal 
fibromuscular cells. XIAP expression was typically 
diffused in the cytoplasm; however, a discrete 
supranuclear staining in coarse clusters was 
observed. On regions of benign prostatic hyperplasia 
(BPH), XIAP showed the lowest expression. XIAP 
expression in PC was shown to be significantly 
higher when compared to PIN, NP and BPH 
(Seligson et al., 2007). In a small cohort, it was found 
that higher levels of XIAP was associated with 
longer relapse-free survival (Krajewska et al., 2003); 
additionally, in another study, patients with positive 
immunostaining for XIAP had a better prognosis, 
which led to questions concerning the pro-tumor role 
of this IAP in prostate cancer (Rodrèguez-
Berriguette et al., 2015).  
The higher expression of XIAP also predicted the 
reduced risk of tumor recurrence in dichotomized 
and continuous variable in univariate analysis. When 
analyzing patients with primary low-grade cancer, 
none which had a high expression of XIAP displayed 
tumor recurrence (n=23). In contrast, patients with 
low levels of XIAP experienced tumor recurrence 
(n=89). The same study showed that patients with 
higher grade or non-confined tumors with an 
elevated XIAP expression have a better prognosis, 
when analyzing the group, when compared to those 
patients that express low levels of XIAP. An 
example of this finding is that 50% of patients whose 
tumors were not confined to the organ (n =92) had 
tumor recurrence, whereas the 12 patients with 
higher levels of XIAP did not experience recurrence. 
Patients with low grade tumors and low XIAP levels 
experienced recurrence (more than 25%), whereas 
none of the patients with higher levels of XIAP had 
recurrence of the tumors. In the PSA follow-up, 94% 
of patients that presented higher levels of XIAP were 
recurrence-free, against 58% of patients with lower 
XIAP levels (SELIGSON et al., 2007).  
XIAP was found to constitutively express on DU145 
cells, playing an important role on modulating 
chemosensitivity (Amantana et al., 2004), the 
presence of XIAP was also found on PC3 cells on 
immunohistochemistry assays showing that XIAP 
was localized mainly on the perinuclear region of 
this cells (Mceleney et al., 2002). 
Thyroid cancer 
XIAP elevated expression had been associated with 
a high degree of invasiveness, being related to lymph 
node metastasis in papillary thyroid cancer (Gu et al., 
2010), and also was associated with old age, 
extrathyroidal extension, tumor size, nodal 
involvement, tall-cell variant, advanced stage 
disease, and significantly poor disease-free survival 
(Hussain et al., 2015).  
XAF1 (XIAP-associated factor-1) antagonizes 
XIAP-mediated caspase inhibition. Loss of XAF1 
expression correlates with tumor progression. It has 
been suggested that the G allele of rs34195599 of 
XAF1 may be a risk factor for the 
clinicopathological features of papillary thyroid 
carcinoma (Kim et al., 2013).  
XIAP expression varied from 48.8% (Hussain et al., 
2015) to 83% in papillary thyroid cancer (Xiao et al., 
2007) and it was of 25% of insular carcinoma only 
moderate positive and non-staining in follicular, 
medullary, anaplastic carcinomas, oncocytic 
neoplasms (Xiao et al., 2007). In another study XIAP 
expression was positive in 75% of patients, whose 
expression was significantly associated with the 
presence of lateral cervical lymph node metastases. 
Additionally, XIAP expression was more frequent in 
BRAFV600E mutated PTCs than in BRAF wild type 
PTCs (Yim et al., 2014), however no correlation 
between these two markers were observed (Gu et al., 
2009).  
In papillary thyroid cancer, XIAP expression was 
associated with phosphorylated AKT, BCL2L1, and 
Ki67 proteins leading to increase cell proliferation 
and reduced apoptosis rate that was reverted with 
treatment with embelin (Hussain et al., 2015).  
TPC-1 and BCPAP cell lines silenced for NFKB1 
and treated with radiation (131I treatment) 
demonstrated a decrease in cell viability mediated by 
XIAP and BIRC2 reduction levels and increased is 
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CASP3 levels, demonstrating an induction of 
apoptosis cascade (Chen et al.,2018). The cell line 
TPC-1 treated with HSP90 inhibitor promoted cell 
apoptosis and tumor decreased size caused by 
inhibition of IAP members, such as XIAP, BIRC5, 
and BIRC2 (Kim et al., 2016). 
In follicular thyroid carcinoma, XIAP expression 
was observed in comparison to non-tumoral thyroid 
tissue. Additionally, XIAP silencing reverted 
malignant phenotype, causing a decrease in cell 
proliferation and an increase in cell apoptosis rate 
(Werner et al., 2017).  
In anaplastic thyroid carcinoma, similar results were 
observed in patients' tissues where XIAP expression 
was significantly elevated in the invasive area of 
anaplastic thyroid carcinoma samples, while XIAP 
expression was negative in either normal thyroid 
follicular epithelial cells or differentiated papillary 
thyroid carcinoma. Moreover, silencing XIAP in 
vitro decreased cancer cell proliferation, migration 
and invasion (Liu et al., 2017).  
For anaplastic thyroid carcinoma, it was 
demonstrated that XIAP repression may be caused 
by overexpression of miR-618 (Cheng et al., 2014).  
In medullary thyroid carcinoma elevated BIRC5 or 
XIAP expression was associated with metastatic 
condition. XIAP, as well as BIRC5 levels, were 
negatively associated with patient survival (Werner 
et al., 2016). 
To be noted 
Pharmacological advances targeting XIAP in 
cancer  
Development of XIAP inhibitors has been explored 
in the last few years with significant advances. The 
use of mimetics has gained considerable attention, 
especially concerning their pharmacological and 
physiochemical properties. One strategy refers to 
employing modifications in amino acids, such as 
using non-natural amino acids, replacing some 
residues - e.g. P2 and P3 -, and modifying the C-
terminal region. These approaches have been 
carefully reviewed in Jaquith (2014). Another 
strategy refers to the development of antagonists of 
XIAP based on the N-terminus of mature Smac, 
where a synthetic compound (GDC-0152) revealed 
interesting results. This compound binds to the XIAP 
BIR3 domain with K(i) values of 28 nM, activating 
apoptosis cell death and, consequently, decreasing 
viability and inhibiting tumor growth of breast 
cancer cell lines and xenografted tumors, 
respectively (Flygare at al., 2012).  
The use of antisense oligonucleotide to target XIAP 
has also been proposed. One example is the 
AEG35156, a second-generation 19-mer antisense 
oligonucleotide, which, in combination with 
docetaxel, has been undergoing clinical trials for 
treatment of locally advanced, metastatic, or 
recurrent solid tumors, such as pancreatic cancer, 
advanced breast cancer, advanced NSCLC and acute 
myeloid leukemia. Side effects were limiting factors 
in the majority of these studies (Tamm, 2006). 
However, a posterior study demonstrated that it is 
generally well tolerated in combination with 
standard chemotherapy in acute myeloid leukemia 
(Katragadda et al., 2013). In fact, a phase II clinical 
trial conducted with patients with advanced 
hepatocellular carcinoma revealed that treatment 
with AEG35156 in combination with sorafenib 
yielded positive results, mainly regarding objective 
responses rates (Lee et al., 2016). 
Using structure-based drug design, a 
nonpeptidomimetic small-molecule functioning as a 
duas antagonist of XIAP and BIRC2, designated AT-
IAP, demonstrated IC50 values in the nM range for 
breast cancer cell lines. Moreover, this compound 
binds to the BIR 3 domain causing disruption of 
XIAP and CASP9 and increased levels of cleaved 
PARP1, indicating activation of apoptosis pathway. 
Additionally, tumor size reduction was demonstrated 
in xenograft models (Tamanini et al., 2017).  
Others XIAP inhibitors have been previously 
reported, however such inhibition was not always in 
a direct-manner. This is the case for embelin, a 
natural product that promotes down-regulation of 
XIAP and was reported to have promising effects in 
leukemia (Hu et al., 2014), pancreatic cancer (Mori 
et al., 2007) and gastric cancer (Wang et al., 2013). 
Funding:  Fundaçao de Amparo à Pesquisa do 
Estado de Sao Paulo (FAPESP) and Coordenaçao de 
Aperfeiçoamento de Pessoal de Nivel Superior 
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